A meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic macular edema.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
dexamethasone 7 endocrinologydiseasesdrugs
diabetic retinopathy 2 endocrinologydiseases

Graph of close proximity drug and disease terms (within 200 characters).

Note: If this graph is empty, then there are no terms that meet the proximity constraint.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
dexamethasone 59 Title: BMC OphthalmologyA meta-analysis of the effect of a dexamethasone intravitreal implant versus intravitreal anti-vascular endothelial growth factor treatment for diabetic
dexamethasone 424 date (collection): /2018AbstractBackgroundThis meta-analysis evaluated the effectiveness and safety of dexamethasone (DEX) implant and intravitreal anti-vascular endothelial growth factor (VEGF) treatment for diabetic
dexamethasone 7309 Cochrane Library, up to August 2017 (Additional file 2, Table 1). Keywords, including macular edema, dexamethasone intravitreal implant, dexamethasone, anti-VEGF, and Ozurdex were used to maxmise the search accuracy.
dexamethasone 7345 (Additional file 2, Table 1). Keywords, including macular edema, dexamethasone intravitreal implant, dexamethasone , anti-VEGF, and Ozurdex were used to maxmise the search accuracy. The literature selections are shown
dexamethasone 14559 all included studies, the dose of the DEX implant was the same. However, in the study by Shah et al., dexamethasone (0.7 mg) was given every 3 months instead of every 4 months as in the other included studies. Among
dexamethasone 26528 which found exhibited no significant effect for pseudophakic eyes. Compared to 10.4 letters in the dexamethasone group, the mean change in BCVA for the bevacizumab group was 7.7 letters (P = 0.47). Moreover, visual
dexamethasone 29100 implant—$9446, bevacizumab—$2013–$4260, and ranibizumab—$19,251–$23,119 [[39]].Currently, dexamethasone delivery systems and anti-VEGF therapies have a positive effect on the course of DME. However, these
Select Disease Character Offset Disease Term Instance
diabetic retinopathy 2728 space within the retina [[1], [2]]. Diabetic macular edema (DME) is macular thickening secondary to diabetic retinopathy (DR) that may be present in any of the stages of this disease, although it manifests more commonly in
diabetic retinopathy 2873 in any of the stages of this disease, although it manifests more commonly in the non-proliferative diabetic retinopathy stage. In patients with DR, aged 20 to 79 years, the global prevalence for DME is 6.8% [[3]]. The prevalence

You must be authorized to submit a review.